t(6;17)(p21;p13) associated with t(3;3)(q21;q26.2) in AML by Zamecnikova, Adriana
Case Report Section 
Atlas Genet Cytogenet Oncol Haematol. 2019; 23(7) 213 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
INIST-CNRS OPEN ACCESS JOURNAL 
t(6;17)(p21;p13) associated with 
t(3;3)(q21;q26.2) in AML 
Adriana Zamecnikova 
Kuwait Cancer Control Center, Kuwait annaadria@yahoo.com 
Published in Atlas Database: January 2018 
Online updated version : http://AtlasGeneticsOncology.org/Reports/t0617p21p13AdrianaMECOMID100092.html 
Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/70476/01-2018-t0617p21p13AdrianaMECOMID100092.pdf 
DOI: 10.4267/2042/70476
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2019 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
Abstract 
Case report on t(6;17)(p21;p13) associated with 
t(3;3)(q21;q26.2) in AML. 
Clinics 
Age and sex 
25 years old female patient. 
Previous history 
Preleukemia; no previous malignancy, no inborn 
condition of note  
Organomegaly 
No hepatomegaly , no splenomegaly , no enlarged 
lymph nodes , no central nervous system 
involvement  
Blood 
WBC: 20X 109/l 
HB: 86g/dl 
Platelets: 14X 109/l 
Blasts: 12% 
Bone marrow: Hyperplastic bone marrow with 
dyserythropoiesis, megaloblastic erythropoiesis, 
presence of multinuclear forms, depressed 
megakaryocytes and 23% blasts. 
Cyto-Pathology 
Classification 
Phenotype: Acute myeloid leukemia 
Immunophenotype 
Positive for CD13, CD33, CD34, HLDR, CS45, 
CD11b, MPO and CD64, dim expression of CD14 
and CD117. 
Diagnosis 
AML with t(3;3)(q21;q26.2) 
Survival 
Date of diagnosis: 12-2017 
Complete remission: no   
Last follow up: 12-2017 
Karyotype 
Sample bone marrow 




7[14]/45,XY,t(3;3)(q21;q26.2),-7[4]/ 46,XX [2] 
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Figure 1. Karyotype of the patient with t(3;3)(q21;q26.2) and -7 (A) and with t(6;17)(p21;p13) as an additional anomaly (B) 
. 
Other molecular cytogenetics technics 
Fluorescence in situ hybridization studies (FISH) 
were performed using Kreatechô MECOM (EVI1) 
t(3;3); inv(3)(3q26) Break FISH probe and 
SureFISH 17p13.3 (PAFAH1B1) and RUNX2 
(6p21.1) probes. 
Other molecular cytogenetics results 
Hybridization with EVI1 probe confirmed the 
rearrangement of the gene as a result of 
t(3;3)(q21;q36.2) on 10 metaphases and in 90 % of 
interphase cells. Hybridization with Vysis D7S486/ 
Vysis CEP 7 probe showed monosomy 7 in 90% of 
cells. FISH studies with SureFISH PAFAH1B1 and 
RUNX2 probes showed normal signals on 2 
metaphases without t(6;17) and juxtaposition of 
PAFAH1B1 from 17p13.3 to 6p21.1 at the site of 
RUNX2 gene in 5 metaphases. 
Comments 
We described here an AML patient with 
t(3;3)(q21;q26.2) associated with monosomy 7 and a 
rare translocation t(6;17)(p21;p13) (La Starza et al., 
26). The chromosomal t(6;17)(p21;p13) was found 
in a  sideline as an additional anomaly to 
t(3;3)(q21;q26.2) and monosomy 7, therefore likely 
representing a secondary aberration to these primary 
anomalies. inv(3)(q21q26.2) or t(3;3)(q21;q26.2) in 
AML or MDS result in deregulation of the proto-
oncogene EVI1 (MECOM), which affect the 
RAS/receptor tyrosine kinase pathway. The 
concomitant monosomy 7 and t(6;17)(p21;p13) are 
probably cooperating genetic lesions that developed 
during malignant transformation processes in our 
patient. 
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Figure 2. (A) Fluorescence in situ hybridization with Kreatechô MECOM (EVI1) break apart probe confirmed the rearrangement 
of the gene as a result of t(3;3)(q21;q36.2). FISH studies with SureFISH PAFAH1B1 located at 17p.13.3 revealed juxtaposition of 
PAFAH1B1 from 17p13.3 to der(6) chromosome (B). Simultaneous hybridization with SureFISH PAFAH1B1 and RUNX2 probes 
showed cohybridization of PAFAH1B1 and RUNX2 genes on 6p21.1 (C). 
References 
La Starza R, Aventin A, Matteucci C, Crescenzi B, Romoli 
S, Testoni N, Pierini V, Ciolli S, Sambani C, Locasciulli A, Di 
Bona E, Lafage-Pochitaloff M, Martelli MF, Marynen P, 
Mecucci C. Genomic gain at 6p21: a new cryptic molecular 
rearrangement in secondary myelodysplastic syndrome and 
acute myeloid leukemia. Leukemia. 2006 Jun;20(6):958-64 
This article should be referenced as such: 
Zamecnikova A. t(6;17)(p21;p13) associated with 
t(3;3)(q21;q26.2) in AML. Atlas Genet Cytogenet Oncol 
Haematol. 2019; 23(7):213-215. 
